BigHat Biosciences raises $75 million in Series C with LG Technology Ventures participation
PUBT · 3d ago
Share
Listen to the news
- BigHat Biosciences closed a USD 75 million Series C to advance its AI-driven protein therapeutics platform and clinical-stage pipeline.
- DFJ Growth, Premji Invest co-led the round; LG Technology Ventures joined as a participating investor.
- Funding targets clinical readouts for BHB810, an AI-designed antibody-drug conjugate in Phase 1, alongside continued platform scaling.
- Proceeds also support BHB299, a T-cell engager in preclinical development, ahead of planned human trials in 2027.
- Total capital raised reached USD 223 million, including an earlier USD 44 million Series B extension closed in 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LG Technology Ventures LLC published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending